Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis

Tomoko Henzan, Koji Nagafuji, Hiroshi Tsukamoto, Toshihiro Miyamoto, Hisashi Gondo, Shinsaku Imashuku, Mine Harada

Research output: Contribution to journalArticlepeer-review

106 Citations (Scopus)


Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder characterized by fever, pancytopenia, hepatosplenomegaly, liver dysfunction, and hemophagocytosis. A 29-year-old woman, diagnosed with systemic lupus erythematosus in 1996, developed HLH in early June 2002. HLH remained refractory during 1.5 months of treatment including corticosteroid, cyclosporine, plasma exchange, vincristine, and etoposide. Infliximab (5 mg/kg/day) was then administered twice. After the second administration, the patient attained remission. Because HLH itself is not a neoplasm but an uncontrolled immune reaction, blocking cytokines involved in the reaction should have therapeutic potentials. For HLH patients not responding to conventional therapy, anticytokine treatment with infliximab may represent one of promising options.

Original languageEnglish
Pages (from-to)59-61
Number of pages3
JournalAmerican Journal of Hematology
Issue number1
Publication statusPublished - Jan 2006

All Science Journal Classification (ASJC) codes

  • Hematology


Dive into the research topics of 'Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis'. Together they form a unique fingerprint.

Cite this